NTRK3 Point Mutations

CI-VAR-00003468Explore in graph →CIViC 3467

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Solid Neoplasm1
NTRK3 Point Mutations	Larotrectinib	Predictive	C	Does Not Support Sensitivity Response	2	submitted	EID9591 In this Phase I study (NCT02122913), which involved 70 heavily pretreated patients with a median age of 59.5 years, with multiple solid tumor types, None of the patients with NTRK point mutations had … (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.